{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:19:31Z","timestamp":1791422371557,"version":"4.3.3"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Amalia Griffini Scholarship"},{"name":"rEVO Biologics"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA188359"],"award-info":[{"award-number":["CA188359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA175577"],"award-info":[{"award-number":["CA175577"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA161048"],"award-info":[{"award-number":["CA161048"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS79274"],"award-info":[{"award-number":["NS79274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.virol.2016.09.012","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T15:04:34Z","timestamp":1474297474000},"page":"121-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Mood stabilizers inhibit cytomegalovirus infection"],"prefix":"10.1016","volume":"499","author":[{"given":"Sara","family":"Ornaghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Gorres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Paidas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony N.","family":"van den Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.virol.2016.09.012_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0009-9236(97)90194-6","article-title":"Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy","volume":"61","author":"Barel","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.virol.2016.09.012_bib2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1399-5618.2010.00828.x","article-title":"Valnoctamide as a valproate substitute with low teratogenic potential in mania: a double-blind, controlled, add-on clinical trial","volume":"12","author":"Bersudsky","year":"2010","journal-title":"Bipolar Disord."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2165\/00003088-199120020-00003","article-title":"Clinical pharmacology of valpromide","volume":"20","author":"Bialer","year":"1991","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF00315032","article-title":"Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects","volume":"38","author":"Bialer","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.virol.2016.09.012_bib5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)","volume":"111","author":"Bialer","year":"2015","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJM199601183340308","article-title":"Antiepileptic drugs","volume":"334","author":"Brodie","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virol.2016.09.012_bib7","doi-asserted-by":"crossref","unstructured":"Brune, W., Hengel, H., Koszinowski U.H., 2001. A mouse model for cytomegalovirus infection. In: Coligan, John E., et al. (Eds.), Current Protocols in Immunology. Chapter 19: Unit 19.7. Epub 2008\/04\/25. \u3008http:\/\/dx.doi.org\/10.1002\/0471142735.im1907s43\u3009. (PubMed PMID: 18432758).","DOI":"10.1002\/0471142735.im1907s43"},{"key":"10.1016\/j.virol.2016.09.012_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-62703-788-4_8","article-title":"Analysis of cytomegalovirus binding\/entry-mediated events","volume":"1119","author":"Chan","year":"2014","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1006\/viro.1993.1192","article-title":"Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate","volume":"193","author":"Compton","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.virol.2016.09.012_bib11","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1038\/cddis.2013.205","article-title":"A proapoptotic effect of valproic acid on progenitors of embryonic stem cell-derived glutamatergic neurons","volume":"4","author":"Fujiki","year":"2013","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.virol.2016.09.012_bib12","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1128\/AAC.00134-08","article-title":"Establishment of a cell-based assay for screening of compounds inhibiting very early events in the cytomegalovirus replication cycle and characterization of a compound identified using the assay","volume":"52","author":"Fukui","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.virol.2016.09.012_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S1473-3099(04)01202-2","article-title":"Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments","volume":"4","author":"Gandhi","year":"2004","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib14","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/JCM.39.2.772-775.2001","article-title":"Quantification of human cytomegalovirus DNA by real-time PCR","volume":"39","author":"Gault","year":"2001","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00113-16","article-title":"Valpromide inhibits lytic cycle reactivation of epstein-barr virus","volume":"7","author":"Gorres","year":"2016","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00148581-200608020-00004","article-title":"Valproate as a mainstay of therapy for pediatric epilepsy","volume":"8","author":"Guerrini","year":"2006","journal-title":"Paediatr. drugs"},{"issue":"8","key":"10.1016\/j.virol.2016.09.012_bib17","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.virol.2016.09.012_bib18","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/JVI.73.6.4552-4560.1999","article-title":"Human cytomegalovirus infection of caco-2 cells occurs at the basolateral membrane and is differentiation state dependent","volume":"73","author":"Jarvis","year":"1999","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.virol.2016.09.012_bib19","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1345\/aph.19211a","article-title":"Comment: potential risk of valproic acid therapy in patients who are HIV-positive","volume":"34","author":"Jennings","year":"2000","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib20","first-page":"91","article-title":"Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid","volume":"16","author":"Kataoka","year":"2013","journal-title":"Int. J. Neuropsychopharmacol. \/ Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP)"},{"issue":"Pt 6","key":"10.1016\/j.virol.2016.09.012_bib21","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1099\/0022-1317-76-6-1409","article-title":"Sodium valproate, an anticonvulsant drug, stimulates human cytomegalovirus replication","volume":"76","author":"Kuntz-Simon","year":"1995","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jcv.2009.08.006","article-title":"Early effects of drugs responsible for DRESS on HHV-6 replication in vitro","volume":"46","author":"Mardivirin","year":"2009","journal-title":"J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol."},{"issue":"5\u20136","key":"10.1016\/j.virol.2016.09.012_bib23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2119\/molmed.2011.00076","article-title":"Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir","volume":"17","author":"Matalon","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.virol.2016.09.012_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.yebeh.2015.02.040","article-title":"Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide--amide derivatives of valproic acid","volume":"46","author":"Mawasi","year":"2015","journal-title":"Epilepsy Behav.: EB"},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pharmthera.2011.04.007","article-title":"Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives","volume":"131","author":"Mercorelli","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bcp.2004.04.013","article-title":"Increased human cytomegalovirus replication in fibroblasts after treatment with therapeutical plasma concentrations of valproic acid","volume":"68","author":"Michaelis","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.virol.2016.09.012_bib27","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1167\/iovs.05-0369","article-title":"Increased replication of human cytomegalovirus in retinal pigment epithelial cells by valproic acid depends on histone deacetylase inhibition","volume":"46","author":"Michaelis","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.virol.2016.09.012_bib28","series-title":"Fields Virology. 2","first-page":"2702","article-title":"Cytomegaloviruses","author":"Mocarski","year":"2007"},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874467210902010095","article-title":"Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection","volume":"2","author":"Monti","year":"2009","journal-title":"Curr. Mol. Pharmacol."},{"issue":"Pt 9","key":"10.1016\/j.virol.2016.09.012_bib30","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1099\/0022-1317-77-9-1993","article-title":"Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels","volume":"77","author":"Moog","year":"1996","journal-title":"J. Gen. Virol."},{"issue":"11","key":"10.1016\/j.virol.2016.09.012_bib31","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1172\/JCI80713","article-title":"Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma","volume":"125","author":"Nakashima","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.virol.2016.09.012_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1600-0773.1991.tb01303.x","article-title":"Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms","volume":"69","author":"Nau","year":"1991","journal-title":"Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdrb.10057","article-title":"Amidic modification of valproic acid reduces skeletal teratogenicity in mice","volume":"71","author":"Okada","year":"2004","journal-title":"Birth Defects Res. Part B: Dev. Reprod. Toxicol."},{"issue":"9","key":"10.1016\/j.virol.2016.09.012_bib34","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1038\/mt.2008.155","article-title":"Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses","volume":"16","author":"Otsuki","year":"2008","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"18","key":"10.1016\/j.virol.2016.09.012_bib35","doi-asserted-by":"crossref","first-page":"9346","DOI":"10.1128\/JVI.00723-11","article-title":"Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways","volume":"85","author":"Paglino","year":"2011","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfs292","article-title":"Exposure to valproic acid inhibits chondrogenesis and osteogenesis in mid-organogenesis mouse limbs","volume":"131","author":"Paradis","year":"2013","journal-title":"Toxicol. Sci.: Off. J. Soc. Toxicol."},{"issue":"10","key":"10.1016\/j.virol.2016.09.012_bib37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"issue":"39","key":"10.1016\/j.virol.2016.09.012_bib38","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00007691-198103000-00012","article-title":"Dipropylacetic acid plasma levels; diurnal fluctuations during chronic treatment with dipropylacetamide","volume":"3","author":"Pisani","year":"1981","journal-title":"Ther. Drug Monit."},{"issue":"5","key":"10.1016\/j.virol.2016.09.012_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1528-1157.1986.tb03582.x","article-title":"Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients","volume":"27","author":"Pisani","year":"1986","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.virol.2016.09.012_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-1211(97)00095-8","article-title":"Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid","volume":"30","author":"Radatz","year":"1998","journal-title":"Epilepsy Res."},{"issue":"24","key":"10.1016\/j.virol.2016.09.012_bib42","doi-asserted-by":"crossref","first-page":"15043","DOI":"10.1128\/JVI.79.24.15043-15053.2005","article-title":"A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals","volume":"79","author":"Ramsburg","year":"2005","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.virol.2016.09.012_bib43","doi-asserted-by":"crossref","first-page":"e3067","DOI":"10.1371\/journal.pone.0003067","article-title":"Unusual repertoire of vocalizations in the BTBR T+tf\/J mouse model of autism","volume":"3","author":"Scattoni","year":"2008","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.virol.2016.09.012_bib44","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/00002030-200005050-00021","article-title":"Valproic acid induces human herpesvirus 8 lytic gene expression in BCBL-1 cells","volume":"14","author":"Shaw","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.virol.2016.09.012_bib45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2015.04.012","article-title":"The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus","volume":"49","author":"Shekh-Ahmad","year":"2015","journal-title":"Epilepsy Behav.: EB"},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/epi.12480","article-title":"Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential","volume":"55","author":"Shekh-Ahmad","year":"2014","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib47","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/cmi.2014.51","article-title":"Immunobiology of congenital cytomegalovirus infection of the central nervous system-the murine cytomegalovirus model","volume":"12","author":"Slavuljica","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"9","key":"10.1016\/j.virol.2016.09.012_bib48","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/epi.12702","article-title":"Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus","volume":"55","author":"Spampanato","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.virol.2016.09.012_bib49","first-page":"144","article-title":"A clinical study in the use of valmethamide, an anxiety-reducing drug","volume":"2","author":"Stepansky","year":"1960","journal-title":"Curr. Ther. Res., Clin. Exp."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1741-4520.2009.00222.x","article-title":"Effects of cytomegalovirus infection on embryogenesis and brain development","volume":"49","author":"Tsutsui","year":"2009","journal-title":"Congenit. Anom."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.taap.2010.08.001","article-title":"Epigenetic modifications in valproic acid-induced teratogenesis","volume":"248","author":"Tung","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.virol.2016.09.012_bib52","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1128\/JVI.76.3.1309-1327.2002","article-title":"Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein","volume":"76","author":"van den Pol","year":"2002","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.virol.2016.09.012_bib53","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1523\/JNEUROSCI.19-24-10948.1999","article-title":"Cytomegalovirus cell tropism, replication, and gene transfer in brain","volume":"19","author":"van den Pol","year":"1999","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"key":"10.1016\/j.virol.2016.09.012_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2015.12.012","article-title":"Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses","volume":"126","author":"Varghese","year":"2016","journal-title":"Antivir. Res."},{"issue":"10","key":"10.1016\/j.virol.2016.09.012_bib55","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1128\/JVI.72.10.8158-8165.1998","article-title":"Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene","volume":"72","author":"Vieira","year":"1998","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib56","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/sj.bjp.0706310","article-title":"Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain","volume":"146","author":"Winkler","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.virol.2016.09.012_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/aid.1997.13.187","article-title":"Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro","volume":"13","author":"Witvrouw","year":"1997","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"6","key":"10.1016\/j.virol.2016.09.012_bib58","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bdi.12325","article-title":"Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice","volume":"17","author":"Wlodarczyk","year":"2015","journal-title":"Bipolar Disord."},{"issue":"13","key":"10.1016\/j.virol.2016.09.012_bib59","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1128\/JVI.00709-15","article-title":"Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors","volume":"89","author":"Wollmann","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2016.09.012_bib60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1743-422X-11-71","article-title":"Resolving the titer of murine cytomegalovirus by plaque assay using the M2-10B4 cell line and a low viscosity overlay","volume":"11","author":"Zurbach","year":"2014","journal-title":"Virol. J."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216302641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682216302641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:37:49Z","timestamp":1758587869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682216302641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":60,"alternative-id":["S0042682216302641"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2016.09.012","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mood stabilizers inhibit cytomegalovirus infection","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2016.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}